Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST
February 03 2015 - 6:09AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM EST on Tuesday, February
10, 2015 to review fourth quarter and year-end 2014 results.
Compugen participants on the conference call will include Martin
Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari
Krashin, CFO. The quarterly and year-end results will be released
on the Company’s website (www.cgen.com), prior to the call.
To access the conference call, please dial 1-888-668-9141 from
the US, or +972-3-918-0609 internationally. The call will also
be available via live webcast through Compugen’s website, located
at the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-782-4291 from the US or
+972-3-925-5904 internationally. The replay will be available
through February 12, 2015.
About Compugen
Compugen is a leading drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug
target candidates, which are then advanced in its Pipeline Program.
The discovery and development of monoclonal antibody therapeutic
candidates against selected Compugen-discovered novel target
candidates is performed by Compugen’s wholly-owned U.S. subsidiary
located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024